Premier Statement on House Passage of FDA User Fee Bill Last Updated: July 12, 2017
Filed under:
Print Friendly, PDF & Email

By Blair Childs, senior vice president of public affairs, Premier

The Premier Inc. healthcare alliance strongly supports provisions in the new House prescription drug user fee authorization bill that would expedite the review of generic drug applications when there are fewer than three manufacturers in the market. We believe this change is fundamental to ensure a healthy, competitive market for generic drugs, and we thank Rep. Schrader (D-OR) and Rep. Bilirakis (R-FL) for their leadership on this issue.

Past experience has proven time and again that when the generic drug market lacks proper competition, hospitals, caregivers and consumers typically experience significant price spikes. Moreover, a dearth of suppliers can leave our national supply chain vulnerable to drug shortages for critical and live-saving drug products used every day in emergency and other procedures. Expedited reviews will help address this problem, and we also thank the Senate for including this provision in their legislation as well. While we applaud these important actions, members of Premier recognize that more needs to be done to create healthy markets for drugs. Premier recently released nine policy recommendations Congress and the administration should take to drive toward the goal of achieving a high-quality, cost-effective pharmaceutical industry, and we will continue to advocate for these and other positive policy changes.

Blair Childs, senior vice president of public affairs, Premier